

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-62) VADACABTAGENE LERALEUCEL

PRONUNCIATION vad'' a kab' ta jeen ler'' a loo' sel

THERAPEUTIC CLAIM Antineoplastic

CHEMICAL DESCRIPTION

The CAR 19-28z fusion receptor is comprised of an engineered CD19-specific murine scFv fused to the transmembrane and cytoplasmic domains of CD28 and to the cytoplasmic domain of the CD3zeta chain

STRUCTURAL FORMULA

Identified Cell Phenotypes in the JCAR015 Investigational Drug

Subsets	Marker	Description
Tcell	CD3+	T lymphocytes
TH	CD4+	Helper T cells
CTL	CD8+	Cytotoxic T lymphocytes
Naïve (TN)	CCR7+CD45RA+ or CD62L+CD45RA+	Naive T cells
Central Memory (TCM)	CCR7+CD45RA- or CD62L+CD45RA-	Central memory T cells
Effector Memory (TEM)	CCR7-CD45RA- or CD62L-CD45RA-	Effector memory T cells
Effector Memory RA (TEMRA)	CCR7-CD45RA+ or CD62L-CD45RA+	Effector memory RA T cells

TRADEMARK None as yet

SPONSOR Juno Therapeutics, Inc.

CODE DESIGNATIONS JCAR015

UNII A4O2H9W17Y

WHO NUMBER 10522

SCS